Literature DB >> 26812004

The potential of protein-nanomaterial interaction for advanced drug delivery.

Qiang Peng1, Huiling Mu2.   

Abstract

Nanomaterials, like nanoparticles, micelles, nano-sheets, nanotubes and quantum dots, have great potentials in biomedical fields. However, their delivery is highly limited by the formation of protein corona upon interaction with endogenous proteins. This new identity, instead of nanomaterial itself, would be the real substance the organs and cells firstly encounter. Consequently, the behavior of nanomaterials in vivo is uncontrollable and some undesired effects may occur, like rapid clearance from blood stream; risk of capillary blockage; loss of targeting capacity; and potential toxicity. Therefore, protein-nanomaterial interaction is a great challenge for nanomaterial systems and should be inhibited. However, this interaction can also be used to functionalize nanomaterials by forming a selected protein corona. Unlike other decoration using exogenous molecules, nanomaterials functionalized by selected protein corona using endogenous proteins would have greater promise for clinical use. In this review, we aim to provide a comprehensive understanding of protein-nanomaterial interaction. Importantly, a discussion about how to use such interaction is launched and some possible applications of such interaction for advanced drug delivery are presented.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cysteine (PubChem CID: 5862); Folic acid (PubChem CID: 6037); Interface; Long-circulation; Nanoparticles; Nanotoxicity; Paclitaxel (PubChem CID: 44155032); Protein corona; SiO(2) (PubChem CID: 24261); Targeting delivery

Mesh:

Substances:

Year:  2016        PMID: 26812004     DOI: 10.1016/j.jconrel.2016.01.041

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  15 in total

1.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

Review 2.  Recent Developments in the Facile Bio-Synthesis of Gold Nanoparticles (AuNPs) and Their Biomedical Applications.

Authors:  Kar Xin Lee; Kamyar Shameli; Yen Pin Yew; Sin-Yeang Teow; Hossein Jahangirian; Roshanak Rafiee-Moghaddam; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2020-01-16

Review 3.  Functional Nucleic Acid Nanomaterials: Development, Properties, and Applications.

Authors:  Wentao Xu; Wanchong He; Zaihui Du; Liye Zhu; Kunlun Huang; Yi Lu; Yunbo Luo
Journal:  Angew Chem Int Ed Engl       Date:  2020-08-25       Impact factor: 16.823

Review 4.  Recent advancements in erythrocytes, platelets, and albumin as delivery systems.

Authors:  Peipei Xu; Ruju Wang; Xiaohui Wang; Jian Ouyang
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

Review 5.  Engineering exosomes as refined biological nanoplatforms for drug delivery.

Authors:  Xin Luan; Kanokwan Sansanaphongpricha; Ila Myers; Hongwei Chen; Hebao Yuan; Duxin Sun
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

Review 6.  Protein corona: a new approach for nanomedicine design.

Authors:  Van Hong Nguyen; Beom-Jin Lee
Journal:  Int J Nanomedicine       Date:  2017-04-18

7.  Antioxidant Nanomaterial Based on Core⁻Shell Silica Nanospheres with Surface-Bound Caffeic Acid: A Promising Vehicle for Oxidation-Sensitive Drugs.

Authors:  Francisco Arriagada; Germán Günther; Jaume Nos; Santi Nonell; Claudio Olea-Azar; Javier Morales
Journal:  Nanomaterials (Basel)       Date:  2019-02-06       Impact factor: 5.076

Review 8.  Immunotoxicity Considerations for Next Generation Cancer Nanomedicines.

Authors:  Gary Hannon; Joanne Lysaght; Neill J Liptrott; Adriele Prina-Mello
Journal:  Adv Sci (Weinh)       Date:  2019-08-01       Impact factor: 16.806

9.  Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.

Authors:  Simon Megy; Stephanie Aguero; David Da Costa; Myriam Lamrayah; Morgane Berthet; Charlotte Primard; Bernard Verrier; Raphael Terreux
Journal:  Nanomaterials (Basel)       Date:  2020-11-05       Impact factor: 5.076

10.  Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice.

Authors:  Aml I Mekkawy; Youssef W Naguib; Suhaila O Alhaj-Suliman; Emad I Wafa; Kareem Ebeid; Timothy Acri; Aliasger K Salem
Journal:  Int J Pharm       Date:  2021-07-10       Impact factor: 6.510

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.